Imatinib-Resistant CML Cells Have Low ENT Activity But Maintain Sensitivity to Gemcitabine

REFERENCES

• Kantarjian , H. M. , O'Brien , S. , Anderlini , P. and Talpaz , M. 1996 . Treatment of myelogenous leukemia: current status and investigational options . Blood. , 87 : 3069 – 3081 .
   PubMed Web of Science ®Google Scholar
• Faderl , S. , Talpaz , M. , Estrov , Z. and Kantarjian , H. M. 1999 . Chronic myelogenous leukemia: biology and therapy . Ann. Intern. Med. , 131 : 207 – 219 .
   PubMed Web of Science ®Google Scholar
• Druker , B. J. , Tamura , S. , Buchdunger , E. , Ohno , S. Segal , G. M. 1996 . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells . Nat. Med. , 2 : 561 – 566 .
   PubMed Web of Science ®Google Scholar
• Kantarjian , H. M. , Cortes , J. , O'Brien , S. , Giles , F. J. Albitar , M. 2002 . Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase . Blood. , 99 : 3547 – 3553 .
   PubMed Web of Science ®Google Scholar
• O'Brien , S. , Giles , F. , Talpaz , M. , Cortes , J. Rios , M. B. 2003 . Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase . Cancer. , 98 : 888 – 893 .
   PubMed Web of Science ®Google Scholar
• Fruehauf , S. , Topaly , J. , Buss , E. C. , Fischer , T. Ottmann , O. G. 2007 . Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis . Cancer. , 109 : 1543 – 1549 .
   PubMed Web of Science ®Google Scholar
• Lech-Maranda , E. , Korycka , A. and Robak , T. 2000 . Influence of gemcitabine (2′,2′-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro . Eur. J. Haematol. , 65 : 317 – 321 .
   PubMed Web of Science ®Google Scholar
• Giovannetti , E. , Mey , V. , Loni , L. , Nannizzi , S. Barsanti , G. 2007 . Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells . Pharmacol. Res. , 55 : 343 – 349 .
   PubMed Web of Science ®Google Scholar
• Baldwin , S. A. , Mackey , J. R. , Cass , C. E. and Young , J. D. 1999 . Nucleoside transporters: molecular biology and implications for therapeutic development . Mol. Med. Today. , 5 : 216 – 224 .
   PubMedGoogle Scholar
• Clarke , M. L. , Mackey , J. R. , Baldwin , S. A. , Young , J. D. and Cass , C. E. 2002 . The role of membrane transporters in cellular resistance to anticancer nucleoside drugs . Cancer Treat. Res. , 112 : 27 – 47 .
   PubMedGoogle Scholar
• Galmarini , C. M. , Mackey , J. R. and Dumontet , C. 2002 . Nucleoside analogues and nucleobases in cancer treatment . Lancet Oncol. , 3 : 415 – 424 .
   PubMed Web of Science ®Google Scholar
• Huang , M. , Wang , Y. , Cogut , S. B. , Mitchell , B. S. and Graves , L. M. 2003 . Inhibition of nucleoside transport by protein kinase inhibitors . J. Pharmacol. Exp. Ther. , 304 : 753 – 760 .
   PubMed Web of Science ®Google Scholar
• Livak , K. J. and Schmittgen , T. D. 2001 . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method . Methods. , 25 : 402 – 408 .
   PubMed Web of Science ®Google Scholar
• Wang , J. , Schaner , M. E. , Thomassen , S. , Su , S. F. Piquette-Miller , M. 1997 . Functional and molecular characteristics of Na(+)-dependent nucleoside transporters . Pharm. Res. , 14 : 1524 – 1532 .
   PubMed Web of Science ®Google Scholar
• Gray , J. H. , Owen , R. P. and Giacomini , K. M. 2004 . The concentrative nucleoside transporter family, SLC28 . Pflugers Arch. , 447 : 728 – 734 .
   PubMed Web of Science ®Google Scholar
• Pastor-Anglada , M. , Felipe , A. and Casado , F. J. 1998 . Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies . Trends Pharmacol. Sci. , 19 : 424 – 430 .
   PubMed Web of Science ®Google Scholar
• Damaraju , V. L. , Damaraju , S. , Young , J. D. , Baldwin , S. A. Mackey , J. 2003 . Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy . Oncogene. , 22 : 7524 – 7536 .
   PubMed Web of Science ®Google Scholar
• Garcia-Manteiga , J. , Molina-Arcas , M. , Casado , F. J. , Mazo , A. and Pastor-Anglada , M. 2003 . Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity . Clin. Cancer Res. , 9 : 5000 – 5008 .
   PubMed Web of Science ®Google Scholar